The results of the present study indicate that DAPK1 methylation may be associated with resistance to imatinib therapy in CML patients; however, this is dependent on the type of mutation causing the resistance. This evidence concerns the gene DAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive.